Inclisiran : new era of lipid-lowering therapy?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083846" target="_blank" >RIV/00023001:_____/23:00083846 - isvavai.cz</a>
Result on the web
<a href="https://www.e-coretvasa.cz/pdfs/cor/2023/01/09.pdf" target="_blank" >https://www.e-coretvasa.cz/pdfs/cor/2023/01/09.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.33678/cor.2022.043" target="_blank" >10.33678/cor.2022.043</a>
Alternative languages
Result language
angličtina
Original language name
Inclisiran : new era of lipid-lowering therapy?
Original language description
Dyslipidemia is the most frequent metabolic abnormality in western world population and a major risk factor for coronary artery disease (CAD) development. Dyslipidemia treatment is still insufficient and achieving target LDL-level infrequent. Statins are a cornerstone of dyslipidemia management. Although statins are one of the safest drugs on the market, statin therapy can be associated with muscle symptoms and increased risk of DM development. Statin discontinuation is frequent, often driven by negative media coverage. Inclisiran is a therapeutic oligonucleotide that employs RNA interference and inhibits the translation of PCSK9-mRNA leading to long-lasting LDL-cholesterol lowering. LDL-cholesterol-lowering effect of inclisiran is reversed at the rate of approximately 2% per month, so the effect of a single dose persists up to approximately two years. When administered once every six months, inclisiran therapy decreases the level circulating LDL-cholesterol by 50–55% and up to 65% in selected patient populations. Inclisiran therapy is not associated with alterations in platelet count, blood lymphocyte, monocyte or neutrophil count, does not cause alterations in blood TNF-alpha or IL-6 concentrations and does not induce relevant anti-drug antibodies. The only relevant side effect is an adverse reaction at the injection site. Inclisiran thus has the potential to become widely prescribed drug that will greatly contribute to dyslipidemia management and further decrease of CAD incidence. © 2023, ČKS.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cor et vasa
ISSN
0010-8650
e-ISSN
1803-7712
Volume of the periodical
65
Issue of the periodical within the volume
1
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
7
Pages from-to
69-75
UT code for WoS article
000959862100009
EID of the result in the Scopus database
2-s2.0-85151274363